WALTHAM, Mass. and DUBLIN, Ireland — November 26, 2025 — Leads & Copy — Mural Oncology plc (Nasdaq: MURA) has announced the final determination of the Additional Price Per Share related to its transaction agreement with XOMA Royalty Corporation (Nasdaq: XOMA) and XRA 5 Corp.
According to Clause 2.4 of the Transaction Agreement, the Additional Price Per Share is $0.000. The total cash consideration payable to Mural shareholders upon the Acquisition’s closing will be $2.035 per share.
XOMA Royalty, Sub, and Mural previously announced on August 20, 2025, that they had entered into a Transaction Agreement. Through this agreement, Sub, a wholly-owned subsidiary of XOMA Royalty, agreed to acquire all issued and to-be-issued share capital of Mural via an Irish High Court-sanctioned “scheme of arrangement” under Chapter 1 of Part 9 of the Irish Companies Act of 2014.
The Acquisition is expected to close in early December 2025, pending the satisfaction of closing conditions and the Irish High Court’s sanction of the Scheme.
Enquiries
ir@muraloncology.com
Lucid Capital Markets, LLC (Financial Adviser to Mural)
570 Lexington Ave, 40th Floor
New York, NY 10022
Cautionary Note Regarding Forward-Looking Statements
This announcement contains forward-looking statements regarding Mural, XOMA Royalty, or Sub’s future intentions. These statements are identified by terms such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “believe”, “will”, “may”, “would”, “could” or “should”. Factors such as closing conditions for the Acquisition not being satisfied or waived, failure to receive sanction of the Scheme by the Irish High Court, Mural’s business risks, and XOMA Royalty’s potential risks could cause actual results to differ materially.
Mural, XOMA Royalty, and Sub do not undertake any obligation to update or revise these statements unless legally required.
Statement Required by the Irish Takeover Rules
Mural’s directors accept responsibility for the announcement’s information, believing it to be factually accurate and complete.
Disclosure Requirements of the Irish Takeover Rules
Under Rule 8.3(b), individuals “interested” in 1% or more of Mural’s “relevant securities” must disclose all “dealings” during the “offer period” by 3:30pm (U.S. Eastern Time) on the following “business day”. All “dealings” in Mural’s “relevant securities” by a bidder or parties acting in concert must be disclosed by 12:00 noon (U.S. Eastern Time) the following business day. Two or more persons cooperating to acquire an “interest” are deemed a single entity under Rule 8.3(a) and (b).
“Interests in securities” arise with long economic exposure to price changes. Terms in quotation marks are defined in the Irish Takeover Rules, available at www.irishtakeoverpanel.ie. For disclosure questions, consult the Irish Takeover Panel at +353 1 678 9020.
General
The release, publication, or distribution of this announcement may be restricted in certain jurisdictions. Copies of this announcement are not being distributed in such restricted jurisdictions. Mural, XOMA Royalty and Sub disclaim responsibility for violations of these restrictions.
Publication on a Website
A copy of this announcement will be available on Mural’s website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication.
Contact:
ir@muraloncology.com
Source: Mural Oncology plc
